Imbed Biosciences Secures Undisclosed Investment From BioLab Holdings
Imbed Biosciences, a synthetic antimicrobial and tissue‑regeneration solutions company, announced an undisclosed investment from BioLab Holdings to accelerate development of its SAM Antimicrobial Technology platform for wound‑care. The funding will support product development and commercialization efforts. The deal was reported on February 4, 2026.
Novartis to Acquire Avidity Biosciences in $12B Takeover
Swiss pharma giant Novartis announced it will acquire RNA‑drug developer Avidity Biosciences for $12 billion, with the transaction expected to close in the next few months. The deal is part of Novartis' strategy to bolster its pipeline amid significant patent expiries,...
Stratus Medical Raises $10M in Series B Funding
Stratus Medical, a Magnolia, TX‑based medical device company, announced a $10 million Series B round led by Wasatch Health Partners. The funding will support development of its RF generator and BVNA technology, expand its patent portfolio, and fund a clinical study.
Ecovia Bio Secures Series B Funding Led by Pointe Angels
Ecovia Bio, a Michigan-based biotech firm specializing in sustainable biopolymers, announced the closing of a Series B funding round led by Pointe Angels. The capital will be used to expand manufacturing capacity at its Livonia facility to meet rising demand...
Good Culture Secures $55M Investment From SEMCAP Food & Nutrition and L Catterton
Austin-based cultured dairy brand Good Culture announced a $55 million funding round. The round was led by SEMCAP Food & Nutrition, which joined existing majority investor L Catterton. The capital will fuel growth, accelerate product innovation, and expand distribution across...
Automata Secures $45M Series C Funding Led by Dimension
Automata, a lab automation company, announced the close of a $45 million Series C round led by Dimension, with participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures, Entrepreneurs First and others. The round also includes a strategic investment partnership...
Moderna Partners with Recordati on Rare Disease mRNA Therapy in up to $160M Deal
Moderna and Italy’s Recordati announced a partnership to develop and commercialize mRNA‑3927 for propionic acidemia. Recordati will pay up to $160 million in upfront and milestone payments and receive royalties, while Moderna will lead clinical development and manufacturing and Recordati will...
AstraZeneca Signs $1.2B Upfront Deal with CSPC for Obesity Assets
AstraZeneca announced a partnership with China's CSPC Pharmaceutical Group, paying $1.2 billion upfront for exclusive ex‑China rights to eight obesity and diabetes programs, including the GLP‑1R/GIPR agonist SYH2082. The total deal value is projected at $18.5 billion, marking one of AZ's largest...
Agomab Therapeutics Targets $182M Nasdaq IPO to Fund Fibrosis Pipeline
Belgian biotech Agomab Therapeutics announced plans for a Nasdaq IPO to raise approximately $182 million in net proceeds. The capital will support the development of its fibrosis drug pipeline, with the company aiming to sell 12.5 million shares. The offering...
Stellular Bio Secures Undisclosed Series 1 Funding Led by Ziff Capital Partners
Stellular Bio, a Watertown, MA-based platelet-derived regenerative biologic therapeutics company, announced it has raised an undisclosed amount in a Series 1 funding round. The round was led by Ziff Capital Partners with participation from Cockrell Interests and other investors. The...
Elysium Therapeutics Secures $7.5M SAFE Funding to Accelerate Opioid Overdose Treatment
Elysium Therapeutics, a biopharmaceutical company based in Lyons, Colorado, announced it closed a $7.5 million SAFE round to accelerate development of its Synthetic Opioid Overdose Prevention and Reversal (SOOPR) technology. The funding will support further advancement of its opioid antagonist and...
Eikon Therapeutics Prices IPO, Targets $318M Raise
Eikon Therapeutics, the biotech startup founded by former MSD R&D head Roger Perlmutter, announced pricing of its Nasdaq IPO at $16‑$18 per share, aiming to raise up to $318 million and achieve a valuation above $900 million. The company will list under...
Veradermics Targets $181.8M Net Proceeds in Upcoming IPO
Biotech firm Veradermics, developing an oral version of Rogaine, announced plans to go public and raise approximately $181.8 million in net proceeds. The proposed IPO will fund late‑stage testing and commercialization of its hair‑loss treatment.
Cellares Secures $257M Series D Funding to Accelerate Global Expansion and Target 2027 IPO
Clinical-stage cell therapy manufacturer Cellares announced a $257 million Series D funding round to support its global expansion and commercial rollout. The capital will also fund preparations for a planned initial public offering in 2027, highlighting investor confidence in its...
CraniUS Therapeutics Secures $20M Series B Funding to Accelerate NeuroPASS Development
CraniUS Therapeutics, a Baltimore‑based neurotechnology firm, announced a $20 million Series B round, with $19 million from private investors and $1 million non‑dilutive funding from the State of Maryland. The capital will be used to accelerate development of its fully implantable, skull‑embedded platform, NeuroPASS.
SamanTree Medical Secures €20M Funding Led by European Investment Bank
Belgium‑based surgical imaging firm SamanTree Medical announced a €20 million funding round led by the European Investment Bank. The capital will be used to advance R&D and further develop its Histolog Scanner for real‑time cancer surgery imaging. The company, founded in...
BridGene Biosciences Secures $28M Series B+ Funding
BridGene Biosciences, a biotech firm developing small‑molecule drugs for hard‑to‑drug targets, announced the closing of a $28 million Series B+ financing round. The round was led by Bayland Capital with participation from GTJA Investment Group, Proxima Ventures, Lapam Capital and Grains Valley...
Boehringer Ingelheim to Acquire IBD Bispecific From Simcere for €42M
German pharma Boehringer Ingelheim has agreed to pay €42 million upfront to Shanghai-based Simcere Pharmaceutical for an IBD bispecific drug candidate, marking a new partnership in immunology.
Fortitude Biomedicines Secures $13M Seed Funding
Fortitude Biomedicines, a Waltham‑based developer of immune‑cell targeting biologics, announced a $13 million seed financing round. The round was co‑led by K2 Bio Partners, Shanghai Healthcare Angel Capital and Elikon Venture, with participation from Everjoy Fortune and Taihill Venture. The funds...
Antheia Secures $24M in Series C Second Close Led by ATHOS KG and America’s Frontier Fund
Antheia, a Menlo Park-based biosynthesis company, announced a second close of its Series C round, raising an additional $24 million. The financing was led by ATHOS KG and America’s Frontier Fund, with participation from existing investors such as Global Health...
Insilico Medicine Secures $120M Drug Discovery Pact with Qilu Pharma
Insilico Medicine announced a $120 million partnership with Chinese pharmaceutical firm Qilu Pharma to develop cardiometabolic therapies. The collaboration will leverage Insilico's AI-driven drug discovery platform to accelerate the identification of novel candidates. The deal highlights growing interest in AI-powered...
Siegfried Acquires Noramco Group's API Assets, Enabling Halo Pharma's Standalone CDMO Transition
SK Capital Partners has agreed to sell the active pharmaceutical ingredient (API) assets of the Noramco Group to Swiss contract manufacturer Siegfried, as announced in a Jan 27 2026 press release. The divestiture allows Halo Pharma to become a dedicated North American...
TRexBio Raises $50M in Series B Extension for Treg Clinical Development
Bay Area biotech TRexBio announced an additional $50 million to its 2024 Series B round, aimed at advancing its pipeline of regulatory T cell (Treg) candidates into clinical trials. The funding will support further development and expansion of its immunotherapy...
Mirum Pharmaceuticals Acquires Bluejay Therapeutics, Adding Brelovitug for HDV
Mirum Pharmaceuticals completed its acquisition of Bluejay Therapeutics, adding the Phase 3 antibody brelovitug for chronic hepatitis delta virus (HDV) to its pipeline. The deal integrates Bluejay’s team and assets, aiming to finish the AZURE Phase 3 program and prepare for potential...
Maia Farms Secures $3.75M Seed Funding Led by Active Impact Investments
Maia Farms, a Vancouver‑based developer of mushroom and mycelium‑based food ingredients, closed a $3.75 million seed round. The financing was led by Active Impact Investments with participation from Nya Planet, Ag‑West Bio, PIC Investment Group and Deep Checks. The capital will...
PAQ Therapeutics Secures $77M in Series B Extension Funding
PAQ Therapeutics, a clinical-stage oncology biotech, announced a Series B extension that brings its total Series B funding to $77 million. The capital will support Phase 1 development of KRAS degrader PT0253 and further clinical advancement of PT0511, with participation from existing and new...
Healthier Capital Leads Seed Funding for Diploid Genomics, Inc.
Diploid Genomics, Inc., an AI‑driven genomics analytics startup, announced its launch and the closing of a seed round led by Healthier Capital, which joins as co‑founder and sole external investor. The round, which closed in January 2026, provides strategic capital...
VentureMed Group Raises $28M in Series C Funding
Minneapolis‑based medical device maker VentureMed Group announced a $28 million Series C round to advance its vessel preparation technologies. The round was led by S3 Ventures with participation from existing investor Endeavour Vision. The funds will support clinical program expansion and new...
Erasca Announces Upsized Public Offering of Common Stock
Erasca announced the pricing of an upsized public offering of its common stock, aiming to raise over $500 million. The offering, part of a broader $500M+ target for several biotech firms, was disclosed in a press release on Jan. 22,...
BioMarin Veterans Launch New Biotech, Raise $82M for Rare Disease Drug Development
Former BioMarin executives have founded a new biotech focused on rare disease therapeutics. The startup announced an $82 million fundraising round to support development of orphan drugs. The capital will be used to acquire and advance promising rare disease candidates.
Parabilis Secures $305M Crossover Round to Advance Helicon Platform
Parabilis Medicines announced a $305 million crossover financing round, giving the biotech company line of sight to Phase III trials for its lead candidate zolucatetide. The funding will support expansion of its Helicon platform into degrader, RIPTAC and radiopharmaceutical formats. The announcement...
Novo Nordisk Invests in Aspect Biosystems, Expands Partnership to Transfer Cell‑therapy Technologies
Novo Nordisk announced an expanded partnership with Aspect Biosystems, transferring its stem‑cell‑derived islet cell and hypoimmune cell‑engineering technologies. As part of the deal, Novo will make an equity investment and provide research funding to Aspect, though financial terms were not...
L-Nutra Secures $36.5M Series D Funding Led by Mubadala
L-Nutra Inc., the world’s first nutri‑technology company, announced a $36.5 million investment in its Series D round, bringing the total Series D raise to $83.5 million. The round was led by Mubadala Investment Company, an Abu Dhabi sovereign investor. The funding will support L‑Nutra’s...
GSK to Acquire RAPT for $2.2B
GlaxoSmithKline (GSK) announced a $2.2 billion acquisition of biotech firm RAPT, securing its food allergy candidate. The deal was unveiled at the JP Morgan Healthcare Conference, marking a major M&A move in the pharma sector.
Think Bioscience Secures $55M Series A Funding
Think Bioscience announced a $55 million Series A round led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors, with participation from T.A. Springer, CE‑Ventures, MBX Capital, and YK Bioventures. Returning investors AV8 Ventures, CU Innovations, and Buff Gold Ventures...
Shionogi Acquires Pfizer's Stake in ViiV, Doubling Its Ownership
Pfizer announced it will exit the HIV specialist joint venture ViiV, which it co‑founded with GSK. Shionogi will take over Pfizer’s share, doubling its stake in the company. The move reshapes ViiV’s ownership and strengthens Shionogi’s position in the HIV...
Exciva Secures $59M Series B Funding to Advance Alzheimer’s Agitation Drug
Exciva announced a €51 million ($59 million) Series B financing round to fund Phase 2 testing of its candidate drug targeting agitation in Alzheimer’s disease. The capital will support clinical development and expand the company's pipeline.
AstraZeneca Pays $630M to Acquire Full Control of AbelZeta's CAR‑T Therapy C‑CAR031
AstraZeneca has paid $630 million to buy out AbelZeta’s 50 % share of the China development and commercialisation rights to the CAR‑T therapy C‑CAR031, securing full control of the anti‑GPC3 treatment in China. The deal expands AZ’s CAR‑T portfolio following prior acquisitions...
SpyGlass Pharma and AgomAb Therapeutics Launch Nasdaq IPOs
California‑based SpyGlass Pharma and New York‑based AgomAb Therapeutics announced the launch of their Nasdaq IPOs last week, joining the 2026 IPO class. Both firms have not disclosed the amount they expect to raise. SpyGlass will list on the Nasdaq Global Select...
Cytotheryx Secures $60M Series A Funding Led by Ouroboros Family Founders Fund
Cytotheryx, a pre‑clinical cell‑therapy company, raised $60 million in a Series A round led by Ouroboros Family Founders Fund I, LP. The capital will accelerate its liver‑cell platform, expand manufacturing, and support regulatory planning, while the company also announced debt financing for real‑estate...
Sable Secures Pre-Seed Funding From Turret Capital and SOSV
Sable, a New York‑based developer of biotech‑driven consumer beauty solutions, announced it has raised an undisclosed pre‑seed round. The funding was led by Turret Capital and SOSV. Sable will use the capital to launch its brand and further develop its...
Merge Labs Raises $252M to Link Brains and Computers
Merge Labs, a brain‑computer interface startup co‑founded by AI entrepreneur Sam Altman, announced a $252 million fundraising round to develop devices that connect human brains to computers. The capital will be used to advance medical applications before expanding to consumer products.
AbbVie Acquires Drug-Device Factory
Pharmaceutical giant AbbVie announced the acquisition of a drug-device manufacturing facility, expanding its presence in the medical device sector. The deal was reported on January 15, 2026, with financial terms undisclosed.
Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal
Eli Lilly and Nvidia have entered a five‑year partnership valued at up to $1 billion to create an AI laboratory aimed at accelerating drug discovery. The collaboration builds on a prior agreement to build pharma’s largest supercomputer and will leverage Nvidia’s...
Aurora Therapeutics Raises $16M Seed Round From Menlo Ventures
Aurora Therapeutics, a biotech startup co‑founded by Nobel laureate Jennifer Doudna and Fyodor Urnov, announced a $16 million seed round from Menlo Ventures to develop gene‑editing therapies for rare diseases under the FDA’s plausible mechanism pathway. The company will initially target...
Aktis Oncology Lands Biotech's First IPO of 2026, Raising $318M
Aktis Oncology, a radiopharmaceutical startup partnered with Eli Lilly, announced its initial public offering on the Nasdaq, raising $318 million. The IPO marks the first biotech offering of 2026, positioning the company for growth in the radiopharma sector.
Medipost Raises $140M to Expand Korean Stem Cell Therapy to US and Japan
South Korean biotech Medipost announced a $140 million fundraising round to commercialize its allogeneic cell therapy, approved in South Korea since 2012, in the United States and Japan. The capital will support regulatory approvals and market entry in these regions.
Eli Lilly to Acquire Ventyx Biosciences for $1.2B
Eli Lilly announced a $1.2 billion cash acquisition of California‑based Ventyx Biosciences, gaining its oral drug pipeline targeting inflammatory diseases. The deal, expected to close in the first half of 2026 pending approvals, expands Lilly’s portfolio beyond its obesity drugs.
Beacon Therapeutics Raises $75M Series C Led by Goldman Sachs Alternatives
Beacon Therapeutics announced a $75 million Series C financing round to advance its vision treatment pipeline. The round was led by Goldman Sachs Alternatives, with participation from a managing partner of the firm’s life sciences team. The funding aims to...
Alveus Therapeutics Raises $159.8M in Series A to Expand Obesity Drug Pipeline
Alveus Therapeutics announced a $159.8 million Series A funding round on Thursday, aiming to accelerate its obesity drug development and challenge market leaders like tirzepatide and semaglutide. The capital will support the company's push into the space dominated by MariTide....
